SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01872780

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Effect of CYP2C8 E274Q, a Novel 23452 G>T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population

The genotype profile of CYP2C8 was analyzed in a Korean population. Frequency in multi-ethnic population and in vivo functionality of novel null allelic CYP2C8 variant were evaluated.

NCT01872780 Healthy

2 Interventions

Name: Rosiglitazone

Description: single oral administration of 4mg of rosiglitazone
Type: Drug
Group Labels: 2

genetic polymorphism rosiglitazone

Name: CYP2C8 genotype

Description: CYP2C8*11.
Type: Genetic
Group Labels: 2

genetic polymorphism rosiglitazone


Primary Outcomes

Description: 0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h

Measure: AUC

Time: 12hr

Secondary Outcomes

Description: 0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h

Measure: Cmax

Time: 12hr

Purpose: Basic Science

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 E274Q

The Effect of CYP2C8 E274Q, a Novel 23452 G>T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population. --- E274Q ---



HPO Nodes